2025-11-23 - Analysis Report
Okay, here's an analysis of Recursion Pharmaceuticals (RXRX) based on the provided data, formatted as requested:

## Recursion Pharmaceuticals Inc (RXRX) Analysis

Recursion Pharmaceuticals is a clinical-stage biotechnology company leveraging AI to discover, develop, and commercialize novel therapeutics.

### 1. Performance vs. S&P 500 (VOO)

*   **RXRX Cumulative Return:** -32.84%
*   **VOO Cumulative Return:** 36.77%
*   **Absolute Divergence (Current):** -73.9
*   **Divergence Range:** max: 84.0, min: -73.9
*   **Relative Divergence:** 0.0

**Analysis:** RXRX has significantly underperformed the S&P 500 (VOO) over the period examined.  The current divergence is at the lowest end of its historical range, suggesting significant underperformance relative to the market benchmark.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha  | Beta  | Cap(B) |
| :--------- | :----- | :----- | :----- | :---- | :----- |
| 2021-2023  | 22.0%  | 81.0%  | 26.0%  | -0.1  | 5.1    |
| 2022-2024  | 11.0%  | 81.0%  | -10.0% | 0.1   | 3.5    |
| 2023-2025  | 10.0%  | 80.0%  | -50.0% | 0.1   | 2.2    |

**Analysis:**

*   **CAGR:** Shows a declining trend in annual growth rates over the different periods, which might raise concerns about the company's ability to sustain high growth rates.
*   **MDD:** Consistently high MDD values indicate substantial risk and volatility in the stock's performance across all periods.
*   **Alpha:** Indicates a declining trend in generating returns above the benchmark. The negative values in recent periods suggest the stock is underperforming relative to its benchmark.
*   **Beta:** Low Beta values around 0.1 suggest the stock is less sensitive to market movements, which can be both an advantage and a disadvantage depending on market conditions.
*   **Cap(B):** The decreasing trend in market capitalization over the periods could indicate investor concerns or company-specific challenges.

### 2. Recent Stock Price Movement

*   **Current Price:** 4.17
*   **Previous Close:** 3.85
*   **Change:** 8.31%
*   **5-Day Moving Average:** 4.066
*   **20-Day Moving Average:** 4.835
*   **60-Day Moving Average:** 5.0961

**Analysis:**

*   The current price shows a significant increase (8.31%) compared to the previous close, indicating a recent positive price surge.
*   The current price is above the 5-day moving average but below the 20-day and 60-day moving averages. This suggests a short-term upward trend but potentially ongoing resistance from longer-term trends.

### 3. Technical Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 23.43 (Oversold)
*   **PPO:** -1.9678
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (195 shares - Very Safe - MRI:0.90). Monthly invest 1.8% of total investment ($1,000.00). Cash Ratio: 0% on 2025-10-01
*   **Recent (20-day) Relative Divergence Change:** 0.0 (Neutral)
*   **Expected Return:** -497.0%

**Analysis:**

*   The RSI indicates that RXRX is currently in oversold territory, which could suggest a potential for a price rebound.
*   The PPO is negative, indicating that the short-term moving average is below the long-term moving average, generally a bearish signal.
*   Hybrid Signal indicating to Buy all cash and the MRI is 0.9 is bullish, which conflicts with other indicators.
*   The very low (negative) expected return suggests significant concerns about the stock's future performance relative to the S&P 500 over the long term.
*   The significant price jump from the last market data {'price': 4.17, 'previousClose': 3.85, 'change': 8.31} indicates potential short-term volatility and might be related to recent news events (see below).

### 4. Recent News & Significant Events

*   **Positive Sentiment:** The "Recursion (RXRX) Jumps 8% on Bargain-Hunting" headline suggests some investors see value at current prices. Morgan Stanley's price target increase, though slight, also indicates some level of confidence.
*   **Meme Stock Speculation:**  The "Is Recursion Pharmaceuticals a Meme Stock?" headline raises concerns about potential speculative trading and volatility unrelated to fundamentals.
*   **AI Competition:** "Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence (AI) Stock" highlights the competitive landscape in the AI-driven drug discovery space.
*   **CEO & Financial Concerns:**  News about the new CEO and widening losses raises questions about the company's strategic direction and financial stability.

### 4-2. Analyst Opinions

*   **Consensus:** Hold
*   **Mean Rating:** 2.62 (Hold)
*   **Target Price:** $6.33 (Suggests potential upside)
*   **Recent Rating Changes:**  No changes reported, so this is neutral information.

**Analysis:** Analyst opinions are mixed. The "Hold" consensus suggests that analysts are not overwhelmingly positive or negative about the stock. The average target price suggests potential upside from the current price, but it's important to note the wide range in target prices ($3.00 - $10.00).

### 5. Recent Earnings Analysis

| 날짜         | EPS    | 매출     |
| :----------- | :----- | :------- |
| 2025-11-05   | -0.36  | 0.01 B$  |
| 2025-08-05   | -0.41  | 0.02 B$  |
| 2025-05-05   | -0.5   | 0.01 B$  |
| 2024-11-06   | -0.34  | 0.03 B$  |
| 2025-11-05   | -0.34  | 0.03 B$  |

**Analysis:**

*   The company consistently reports negative EPS, indicating ongoing losses.
*   Revenue is relatively low and has fluctuated, suggesting uncertainty in revenue generation.
*   The most recent earning has improvement on EPS, which may improve Hybrid Signal, and attract more investors.

### 6. Financial Information

| Quarter      | Revenue | Profit Margin |
| :----------- | :------ | :-------------- |
| 2025-09-30   | $0.00B  | -194.74%       |
| 2025-06-30   | $0.02B  | -5.54%         |
| 2025-03-31   | $0.01B  | -47.31%        |
| 2024-12-31   | $0.00B  | -183.62%       |
| 2024-09-30   | $0.03B  | 53.69%         |

| Quarter      | Equity    | ROE     |
| :----------- | :-------- | :------ |
| 2025-09-30   | $1.05B   | -15.50% |
| 2025-06-30   | $0.92B   | -18.70% |
| 2025-03-31   | $0.93B   | -21.68% |
| 2024-12-31   | $1.03B   | -17.29% |
| 2024-09-30   | $0.52B   | -18.27% |

**Analysis:**

*   Revenue is inconsistent, with some quarters showing minimal revenue.
*   Profit margins are generally very negative, indicating significant losses for each dollar of revenue.
*   ROE is consistently negative, reflecting the company's inability to generate profits from shareholder equity.
*   Equity fluctuates, which could be due to fundraising activities or losses.

### 7. Overall Summary

Based on the provided data, RXRX presents a high-risk investment opportunity. Here's a summary of key concerns and potential positives:

**Concerns:**

*   **Significant Underperformance:**  Substantially underperforming the S&P 500.
*   **Negative Profitability:** Consistent losses, negative profit margins, and negative ROE.
*   **High Volatility:** Evidenced by the MDD and potential meme stock status.
*   **Uncertain Future:** Low expected return and news highlighting both competition and internal challenges.
*   **Declining CAGR and Alpha:** Suggests weakening performance relative to benchmarks.

**Potential Positives:**

*   **Oversold Condition:** RSI suggests a possible short-term rebound.
*   **Analyst Target Price:** Suggests potential upside.
*   **Recent Price Jump:** May indicate renewed investor interest.
*   **New CEO:** May bring positive strategic changes.
*   **Hybrid Signal:** Hybrid Signal indicating to Buy all cash and the MRI is 0.9 is bullish, which conflicts with other indicators.

**Overall Recommendation:** Due to the significant risks and negative indicators, a cautious approach is warranted.  Investors should carefully weigh the potential risks against the speculative potential for a turnaround based on AI advancements and strategic changes. Further research is strongly recommended before making any investment decisions. The conflicting Hybrid Signal indicates to Buy could be a opportunity, but more data is needed.
